Women Researcher Award
| Jana Wattar |
| Affiliation |
Lebanese International University |
| Country |
Lebanon |
| Scopus ID |
59706254900 |
| Documents |
3 |
| Citations |
3 |
| h-index |
1 |
| Subject Area |
Pharmacology, Toxicology and Pharmaceutical Science |
| Event |
International Academic Achievements & Awards |
Jana Wattar
Lebanese International University (LIU), Lebanon
Jana Wattar is an academic researcher and Assistant Professor in Pharmaceutical Sciences at the Lebanese International University, Beirut, Lebanon. Her scholarly work focuses on nanotechnology-based drug delivery systems, pharmaceutical technology, targeted nanocarriers, and translational nanomedicine for cancer and neurological disorders. Through extensive interdisciplinary collaborations and funded research initiatives, she has contributed to advancing lipid-based nanocarrier systems and innovative therapeutic formulations in the Middle East region.[1]
Her research profile combines expertise in pharmaceutics, pharmaceutical biotechnology, dosage form design, and nanomedicine optimization. Al Wattar has demonstrated active engagement in scientific leadership, academic mentorship, and institutional partnership development while contributing to peer-reviewed scientific literature and international biomedical conferences.[2]
Abstract
This academic profile presents the scientific achievements, scholarly activities, and research contributions of Jana K. Al Wattar in the fields of pharmaceutical sciences and nanomedicine. Her work emphasizes the development of smart lipid-based nanocarriers, targeted drug delivery systems, and nanotechnology-enabled therapeutic strategies for cancer and neurodegenerative disorders. Through funded research, international collaborations, and scientific mentorship, Al Wattar has contributed to translational pharmaceutical innovation and academic development within the Levant region.[3]
Keywords
Nanomedicine, Pharmaceutical Technology, Drug Delivery Systems, Lipid Nanocarriers, Cancer Therapeutics, Neurodegenerative Disorders, Pharmaceutical Biotechnology, Nanovesicles, Pharmaceutics, Theranostics, Pharmaceutical Sciences, Biomaterials, Targeted Therapy.
Introduction
Nanotechnology-based pharmaceutical systems have become increasingly important in addressing challenges associated with drug resistance, low bioavailability, targeted delivery, and therapeutic safety. Researchers working in translational nanomedicine contribute significantly to advancing modern therapeutic systems through innovative drug carrier formulations and multifunctional pharmaceutical platforms.[4]
Jana K. Al Wattar has established a research profile focused on pharmaceutical nanotechnology, drug delivery optimization, and targeted therapeutic applications. Her work integrates pharmaceutical formulation sciences with biomedical innovation to develop advanced nanocarrier systems capable of improving treatment efficacy for cancer and neurological diseases.[5]
Research Profile
Al Wattar currently serves as a full-time Assistant Professor at the Lebanese International University, where she teaches courses in pharmaceutics, dosage forms, pharmaceutical calculations, biotechnology, and pharmaceutical technology. Her academic responsibilities also include research mentorship, laboratory instruction, and student supervision across undergraduate and postgraduate pharmacy programs.[6]
Her research vision focuses on developing smart lipid-based nanocarriers for targeted drug delivery applications in oncology and neurodegenerative disorders. She has secured multiple competitive research grants from institutions including Abu Dhabi University, Al Ain University, and Ras Al Khaimah research initiatives, supporting investigations in nanovesicle optimization, biomaterials, and therapeutic nanotechnology.[7]
In addition to research and teaching activities, Al Wattar has contributed to academic leadership through committee chairmanships, public relations coordination, and the supervision of international academic memoranda of understanding aimed at strengthening regional and international scientific collaboration.[8]
Research Contributions
Al Wattar’s scientific contributions focus on the formulation, characterization, and optimization of nanovesicles, liposomal systems, nanosponges, and electrohydrodynamic drug delivery platforms. Her studies investigate improved therapeutic efficacy, targeted delivery, and enhanced bioavailability of pharmaceutical compounds through advanced nanotechnology-based systems.[9]
Her peer-reviewed research has addressed anticancer nanomedicine, autism-related oxidative stress modulation, smart theranostic liposomal systems, tissue engineering, biomaterials, and innovative nanoscale drug carriers. These investigations contribute to the broader development of precision-targeted pharmaceutical therapies and translational nanomedicine applications.[10]
Al Wattar has also established extensive national and international collaborations involving universities and research institutions across Lebanon, the United Arab Emirates, Jordan, and Egypt. These partnerships support multidisciplinary projects in nanotechnology, pharmaceutical formulation sciences, tissue engineering, and biomedical innovation.[11]
Publications
Jana K. Al Wattar has published research in pharmaceutical nanotechnology, drug delivery systems, and nanomedicine, focusing on lipid nanocarriers, anticancer therapeutics, and neurodegenerative disorders. Her publications in peer-reviewed journals address formulation optimization, nanovesicles, theranostic systems, and targeted therapies, contributing to advancements in translational pharmaceutical and biomedical sciences.
Research Impact
The research activities of Jana K. Al Wattar demonstrate growing impact within pharmaceutical sciences and translational nanomedicine. Her work addressing nanovesicle optimization, targeted anticancer delivery systems, and neurotherapeutic nanocarriers contributes to ongoing scientific efforts aimed at improving therapeutic efficiency and patient outcomes.[17]
Her receipt of multiple research grants, poster awards, oral presentation recognitions, and institutional teaching awards reflects both academic productivity and professional engagement within regional and international scientific communities. Her collaborations across multiple countries further strengthen the translational scope of her research profile.[18]
Award Suitability
Jana K. Al Wattar demonstrates strong suitability for recognition in pharmaceutical sciences and nanomedicine due to her interdisciplinary contributions to drug delivery systems, targeted nanotherapeutics, and translational pharmaceutical research. Her work integrates formulation science, biomedical innovation, and therapeutic optimization in areas of significant scientific and clinical relevance.[19]
Her achievements in research funding acquisition, academic leadership, scientific mentorship, and international collaboration further support her profile as an active contributor to pharmaceutical research and higher education within the Middle East and broader scientific community.[20]
Conclusion
Jana K. Al Wattar has developed a distinguished academic and scientific profile within pharmaceutical sciences through her research in nanotechnology-based drug delivery systems and translational nanomedicine. Her scholarly contributions to anticancer therapeutics, nanovesicle optimization, biomaterials, and pharmaceutical formulation sciences demonstrate sustained research engagement and interdisciplinary collaboration. Through teaching, mentorship, scientific leadership, and funded research activities, she continues to contribute to advancing pharmaceutical innovation and academic excellence in the region.[21]
External Links
References
- Alwattar, J. K., Chouaib, R., Khalil, A., & Mehanna, M. M. (2020). “A novel multifaceted approach for wound healing: Optimization and in vivo evaluation of spray dried tadalafil loaded pro-nanoliposomal powder.” International Journal of Pharmaceutics.
https://doi.org/10.1016/j.ijpharm.2020.119869
- Mehanna, M. M., Sarieddine, R., Alwattar, J. K., et al. (2020). “Anticancer activity of thymoquinone cubic phase nanoparticles against human breast cancer.” International Journal of Nanomedicine.
- Alwattar, J. K., et al. (2021). “Smart stimuli-responsive liposomal nanohybrid systems: A critical review of theranostic behavior in cancer.” Pharmaceutics.
- Alwattar, J. K., & Mehanna, M. M. (2024). “Engineered Porous Beta-Cyclodextrin-Loaded Raloxifene Framework with Potential Anticancer Activity.” International Journal of Nanomedicine.
- Alwattar, J. K., Assi, M., Nasser, S., Rahal, M., & Mehanna, M. M. (2025). “Raloxifene-Loaded Lipid Nanovesicles: A Journey to Select the Optimal Nanocarrier Formulation Through Characterization and Cytotoxic Analysis.” Biomedicines.